Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and othersLed by founder and drug discovery expert Dr. Andreas Goutopoulos, Actithera's proprietary three-pillar discovery platform is designed to enable prolonged radioligand tumor retention  Proceeds will support clinical development of Actithera's fibroblast activation protein (FAP)-targeting candidate and pipeline expansion View original content:https://www.prnewswire.co.uk/news-releases/actithera-raises-75-5m-in-oversubscribed-series-a-financing-to-redefine-precision-radioligand-therapy-302500405.html

en | boerse | 67932672 |